- What is Tisch MSRCNY?
- Our Research
- Stem Cell Trial
- Get Involved
We are currently the only center in the United States that is conducting an FDA approved clinical trial
using stem cells in patients with MS. The goal of the Phase I trial is to determine whether or not the
therapy is safe and effective. We hope that this will lead to additional future trials and that with our
concurrent research, the reversal of disability will become a realistic therapeutic objective.
Achieving our goals requires us to overcome two immediate hurdles. The first is the closure of the animal research facility which we are currently using, scheduled to occur on May 31st, 2015. This
facility is located less than a block away at Roosevelt Hospital, and its closure is a result of Mt. Sinai’s
recent acquisition of St. Luke’s Roosevelt Hospital Center. Unfortunately, it could not come at a worse
time for us as animal research is a critical component of all of the work at the Center, and especially of
our stem cell program. The second critical issue is the need to expand our regenerative disease
program, in particular, our stem cell facility.
Having previously anticipated our needs, we have 10,000 square feet of undeveloped space on the
third floor of the Tisch MS Center slated to be an expanded research facility. This new site will be
designated as the Institute for Experimental and Stem Cell Research at the Tisch MS Research Center
of New York. The cost of the project is roughly $10 million, and construction is expected to take 16
weeks and will commence as soon as funding is secured.
In order to continue our trend of surpassing our academic goals, Tisch MSRCNY urgently needs to
begin the rapid development of the area on the third floor in order to ensure that our studies carry on
without devastating interruptions or delays. We are asking all of our friends, family, advocates, donors,
and supporters to please consider making a gift so we can move ahead with our research plans.
Thank you for your consideration.